To see only press releases which have been disclosed pursuant to legislation or other regulations, please select “Regulatory releases” below.
All releases
English
Annual report and Remuneration report 2023 for Initiator Pharma A/S
Initiator Pharma’s Annual Report 2023 and Remuneration Report 2023 has now been published and is available on the company´s home page.
Initiator Pharma’s pudafensine preclinical pharmacology results published in the British Journal of Pharmacology
Initiator Pharma A/S, a clinical-stage biotech company, today announced that an article titled “A novel reuptake inhibitor induces erection by increasing central dopamine and peripheral nitric oxide release” was published in the prestigious peer-reviewed scientific journal British Journal of Pharmacology.
MAC Clinical Research converts its receivable into shares in Initiator Pharma
The Board of Directors of Initiator Pharma A/S, company reg. (CVR) no. 37663808, (“Initiator” or the “Company”) has today resolved to carry out a capital increase directed at MAC Clinical Research Finance Ltd (“MAC”) in connection with MAC’s conversion notice regarding conversion of outstanding receivable on February 20th.
Issuance of new shares and directed share buyback, as well as the sale of shares in connection with the long-term incentive program for 2021
The Board of Directors of Initiator Pharma A/S, company reg. (CVR) no. 37663808, (“Initiator” or the “Company”) has today resolved to carry out a capital increase directed at members of executive management and key management under the long term incentive program for 2021 (“LTI2021-program”) and to conduct a directed buyback of shares in order to sell shares to the board of directors under the LTI2021-program.
Initiator Pharma expands its position to a broader Sexual Health Franchise and intensifies its business development efforts
Initiator Pharma A/S, a clinical-stage pharma company developing innovative drugs targeting key unmet medical needs within the central and peripheral nervous system, announced today that the company will expand the position of the company to a broader Sexual Health Franchise including both male Erectile Dysfunction (ED) and Female Sexual Dysfunction (FSD) indications. Initiator Pharma will be in San Francisco to present the company at business and investor meetings during the 42nd Annual J.P. Morgan Healthcare Conference January 8 to 11.
Initiator Pharma reports positive statistically significant and clinically relevant Phase IIb efficacy data with pudafensine
Initiator Pharma A/S, a clinical-stage pharma company, today announced positive results from its Phase IIb clinical trial with pudafensine (IP2015) for the treatment of erectile dysfunction (ED). The study data analysis has demonstrated statistically significant and clinically relevant efficacy in ED-related endpoints and no observations of critical adverse events. The positive results, both regarding efficacy and safety, support further development of pudafensine aiming at registration and launch in this patient group with significant unmet medical need.
Result of incentive program LTI2023 in Initiator Pharma
The AGM held on May 26, 2023 approved two long-term incentive programs (“LTI2023”), one for Management and leading employees and one for board members.LTI2023 for Management and leading…